Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance

Z. Charles,E. Pugh,D. Barnett
DOI: https://doi.org/10.1136/hrt.2007.138263
IF: 5.7
2008-04-14
Heart
Abstract:This NICE technology appraisal guidance on ezetimibe for primary (heterozygous-familial and non-familial) hypercholesterolaemia should be read in conjunction with the NICE technology appraisal guidance on the initiation of statin therapy (Technology Appraisal 94) and in the context of the relevant NICE clinical guidelines. The full guidance1 was published in the NICE technology appraisal guidance in November 2007. The guidance was developed using NICE’s multiple technology appraisal process. Further information is available in the Guide to the methods of technology appraisal.2 The main points of the guidance are: The Appraisal Committee considered the different mode of action of ezetimibe from that of statins, and the potential for the addition of ezetimibe to statin therapy to achieve greater reductions in cholesterol than with statin therapy alone. The limitations of current treatment options in lowering cholesterol concentrations to desirable levels among people with primary hypercholesterolaemia were also discussed. Additionally the Appraisal Committee recognised …
What problem does this paper attempt to address?